Company intelligence / Profile preview

KANG LI TAI Pharmaceutical

Shandong Sheng, Chinainsights.citeline.com ↗

Ownership: Private
Development stage: Commercial

Overview

KANG LI TAI Pharmaceutical is a Chinese biotech/pharma company focused on developing biologic drugs, particularly monoclonal antibodies and interleukins, targeting cancer and immune-related diseases. Its lead asset, KLT‑1101, targets the interleukin‑12 receptor and is in a Phase 1/2 trial for advanced malignant solid tumors. Other pipeline assets are in discovery stages targeting hematologic diseases and neoplasms. The company has at least four programs in its pipeline but no approved products as of June 2025. No published clinical results are available.

Therapeutic areas: OncologyHematology
Modalities: Monoclonal antibodyInterleukin (Biologic)Recombinant polypeptide
Industry: Biotech

Drug pipeline

1 asset

KLT-1101

Unknown

Beyond the preview

Go deeper on KANG LI TAI Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KANG LI TAI Pharmaceutical.

Explore the full profile